Myocardial	myocardial	O	O	O	O
Fas	fas	O	O	O	O
ligand	ligand	O	O	O	O
expression	expression	O	O	O	O
increases	increases	O	O	O	O
susceptibility	susceptibility	O	O	O	O
to	to	O	O	O	O
AZT-induced	azt-induced	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Dilated	dilated	O	DISEASE	OTHERS	I
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
(	(	O	O	O	O
DCM	dcm	O	O	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
myocarditis	myocarditis	O	DISEASE	OTHERS	I
occur	occur	O	O	O	O
in	in	O	O	O	O
many	many	O	O	O	O
HIV-infected	hiv-infected	O	O	O	O
individuals	individuals	O	O	O	O
,	,	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
symptomatic	symptomatic	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
in	in	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Highly	highly	O	O	O	O
active	active	O	O	O	O
antiretroviral	antiretroviral	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
HAART	haart	O	O	O	O
)	)	O	O	O	O
has	has	O	O	O	O
significantly	significantly	O	O	O	O
reduced	reduced	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
of	of	O	O	O	O
acquired	acquired	O	DISEASE	OTHERS	I
immunodeficiency	immunodeficiency	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
AIDS	aids	O	DISEASE	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
has	has	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
and	and	O	O	OTHERS	I
skeletal	skeletal	O	O	OTHERS	I
myopathies	myopathies	O	O	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
AND	and	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
order	order	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
whether	whether	O	O	O	O
the	the	O	O	O	O
HAART	haart	O	O	O	O
component	component	O	O	O	O
zidovudine	zidovudine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
3'-azido-2',3'-deoxythymidine	3'-azido-2',3'-deoxythymidine	O	O	OTHERS	I
;	;	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
triggers	triggers	O	O	O	O
the	the	O	O	O	O
Fas-dependent	fas-dependent	O	O	O	O
cell-death	cell-death	O	O	O	O
pathway	pathway	O	O	O	O
and	and	O	O	O	O
cause	cause	O	O	O	O
cytoskeletal	cytoskeletal	O	O	O	O
disruption	disruption	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
murine	murine	O	O	O	O
model	model	O	O	O	O
of	of	O	O	O	O
DCM	dcm	O	O	OTHERS	I
,	,	O	O	O	O
8-week-old	8-week-old	O	O	O	O
transgenic	transgenic	O	O	O	O
(	(	O	O	O	O
expressing	expressing	O	O	O	O
Fas	fas	O	O	O	O
ligand	ligand	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
myocardium	myocardium	O	O	O	O
:	:	O	O	O	O
FasL	fasl	O	O	O	O
Tg	tg	O	DISEASE	OTHERS	I
)	)	O	O	O	O
and	and	O	O	O	O
non-transgenic	non-transgenic	O	O	O	O
(	(	O	O	O	O
NTg	ntg	O	O	OTHERS	I
)	)	O	O	O	O
mice	mice	O	O	O	O
received	received	O	O	O	O
water	water	O	O	O	O
ad	ad	O	O	OTHERS	I
libitum	libitum	O	O	O	O
containing	containing	O	O	O	O
different	different	O	O	O	O
concentrations	concentrations	O	O	O	O
of	of	O	O	O	O
AZT	azt	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
0	0	O	O	O	O
,	,	O	O	O	O
0.07	0.07	O	O	O	O
,	,	O	O	O	O
0.2	0.2	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
0.7	0.7	O	O	O	O
mg/ml	mg/ml	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
6	6	O	O	O	O
weeks	weeks	O	O	O	O
,	,	O	O	O	O
cardiac	cardiac	O	O	O	O
function	function	O	O	O	O
was	was	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
echocardiography	echocardiography	O	O	O	O
and	and	O	O	O	O
morphology	morphology	O	O	O	O
was	was	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
histopathologic	histopathologic	O	O	O	O
and	and	O	O	O	O
immunohistochemical	immunohistochemical	O	O	O	O
methods	methods	O	O	O	O
.	.	O	O	O	O

NTg	ntg	O	O	OTHERS	I
and	and	O	O	O	O
untreated	untreated	O	O	O	O
FasL	fasl	O	O	O	O
Tg	tg	O	DISEASE	OTHERS	I
mice	mice	O	O	O	O
showed	showed	O	O	O	O
little	little	O	O	O	O
or	or	O	O	O	O
no	no	O	O	O	O
change	change	O	O	O	O
in	in	O	O	O	O
cardiac	cardiac	O	O	O	O
structure	structure	O	O	O	O
or	or	O	O	O	O
function	function	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
contrast	contrast	O	O	OTHERS	I
,	,	O	O	O	O
AZT-treated	azt-treated	O	O	O	O
FasL	fasl	O	O	O	O
Tg	tg	O	DISEASE	OTHERS	I
mice	mice	O	O	O	O
developed	developed	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
dilation	dilation	O	O	OTHERS	I
and	and	O	O	O	O
depressed	depressed	O	DISEASE	OTHERS	I
cardiac	cardiac	O	O	O	O
function	function	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
dose-dependent	dose-dependent	O	O	O	O
manner	manner	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
concomitant	concomitant	O	O	O	O
inflammatory	inflammatory	O	O	O	O
infiltration	infiltration	O	O	O	O
of	of	O	O	O	O
both	both	O	O	O	O
ventricles	ventricles	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
changes	changes	O	O	O	O
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
increased	increased	O	O	O	O
sarcolemmal	sarcolemmal	O	O	O	O
expression	expression	O	O	O	O
of	of	O	O	O	O
Fas	fas	O	O	O	O
and	and	O	O	O	O
FasL	fasl	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
increased	increased	O	O	O	O
activation	activation	O	O	O	O
of	of	O	O	O	O
caspase	caspase	CHEMICALS	O	OTHERS	I
3	3	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
translocation	translocation	O	O	O	O
of	of	O	O	O	O
calpain	calpain	O	O	O	O
1	1	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
sarcolemma	sarcolemma	O	O	O	O
and	and	O	O	O	O
sarcomere	sarcomere	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
increased	increased	O	O	O	O
numbers	numbers	O	O	O	O
of	of	O	O	O	O
cells	cells	O	O	O	O
undergoing	undergoing	O	O	O	O
apoptosis	apoptosis	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
dystrophin	dystrophin	O	O	O	O
and	and	O	O	O	O
cardiac	cardiac	O	O	O	O
troponin	troponin	CHEMICALS	O	OTHERS	I
I	i	CHEMICALS	O	OTHERS	I
localization	localization	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
loss	loss	O	O	O	O
of	of	O	O	O	O
sarcolemmal	sarcolemmal	O	O	O	O
integrity	integrity	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
expression	expression	O	O	O	O
of	of	O	O	O	O
Fas	fas	O	O	O	O
ligand	ligand	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
myocardium	myocardium	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
identified	identified	O	O	O	O
in	in	O	O	O	O
HIV-positive	hiv-positive	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
might	might	O	O	O	O
increase	increase	O	O	O	O
the	the	O	O	O	O
susceptibility	susceptibility	O	O	O	O
to	to	O	O	O	O
HAART-induced	haart-induced	O	O	O	O
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
activation	activation	O	O	O	O
of	of	O	O	O	O
apoptotic	apoptotic	O	O	O	O
pathways	pathways	O	O	O	O
,	,	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
dilation	dilation	O	O	OTHERS	I
and	and	O	O	O	O
dysfunction	dysfunction	O	O	O	O
.	.	O	O	O	O

